Odonate(OTC) ODTC

Market Cap$54.85B

Since IPO (2017)-92%

5 Year-95%

1 Year+17%

1 Month+10%

$50,000.00

+0.00%

+0.00Today

Odonate last closing stock price
Metric	Price	Date
Last close	USD 150,000.00	2025-02-04

Odonate stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+9.65%	USD 136,800.00	2024-06-12
1 month	+9.65%	USD 136,800.00	2024-06-12
3 month	+9.65%	USD 136,800.00	2024-06-12
Year to date	+9.65%	USD 136,800.00	2024-06-12
1 year	+16.82%	USD 128,400.00	2024-02-05
3 year	+44.23%	USD 104,000.00	2022-02-03
5 year	-94.54%	USD 2,746,400.00	2020-02-06
Since inception	-91.85%	USD 1,840,000.00	2017-12-07

Odonate Financials at a Glance

Market Cap

$54.85B

Revenue (TTM)

$0.00

Net Income (TTM)

$31.41M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-0.73 (Low)

Dividend

$0.00

Beta (Volatility)

-0.73 (Low)

Price

$50,000.00

Volume

Open

$50,000.00

Price

$50,000.00

Volume

Open

$50,000.00

Previous Close

$50,000.00

Daily Range

$150,000.00 - $150,000.00

52-Week Range

$150,000.00 - $150,000.00

Estimated Earnings Date

Aug 5, 2026

Dividend

$0.00

Beta (Volatility)

-0.73 (Low)

Price

$50,000.00

Volume

Open

$50,000.00

Previous Close

$50,000.00

Daily Range

$150,000.00 - $150,000.00

52-Week Range

$150,000.00 - $150,000.00

Estimated Earnings Date

Aug 5, 2026

ODTC News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Odonate

Odonate Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer treatments. Established in 2013 and headquartered in New York, the company is primarily advancing tesetaxel, an orally administered chemotherapy drug currently in Phase III clinical trials for metastatic breast cancer.

Products and Services

Primary product in development: tesetaxel for metastatic breast cancer
Focus on oral chemotherapy to improve patient convenience
Commitment to advancing cancer treatment options

Growth Outlook

Phase III clinical study for tesetaxel is a significant milestone
Strong cash position with $48.2 million in cash and short-term investments
Market potential for innovative cancer therapies continues to expand

Financial Highlights

Recent quarterly net income of $4.75 million indicates operational progress
Cash flow from operating activities of $5.47 million supports ongoing development
Low debt ratio of 0.02 suggests strong financial stability

Odonate Therapeutics is positioned in a critical sector of healthcare, focusing on unmet needs in cancer treatment. The ongoing Phase III study of tesetaxel represents a pivotal opportunity for the company to make a significant impact in oncology. With a robust cash position, the company is well-equipped to fund its research and development efforts. The low debt ratio further enhances its financial stability, allowing for strategic investments in future growth. As the market for innovative cancer therapies continues to grow, Odonate Therapeutics stands out as a company with the potential to deliver meaningful advancements in patient care.

AI Generated • Jul 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Kevin C. Tang

Website

www.odonate.com

Headquarters

New York City, NY 10016, US

ODTC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

7.01%

Return on Capital

-0.74%

Return on Assets

6.63%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$54.85B

Shares Outstanding

365.60K

Volume

Avg. Volume

Financials (TTM)

Gross Profit

-$573.00K

Operating Income

$6.23M

EBITDA

-$6.03M

Operating Cash Flow

-$45.35M

Capital Expenditure

-$5.00K

Free Cash Flow

-$45.35M

Cash & ST Invst.

$48.20M

Total Debt

$2.77M

Odonate Performance Analysis

Odonate annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 0	N/A
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A

Odonate sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2021-09-30	N/A
Q4	2021-12-31	N/A
Q3	2022-09-30	N/A
Q4	2022-12-31	N/A

Odonate annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD -146,682.40	N/A
2022	2022-12-31	USD 117,945.60	N/A
2023	2023-12-31	USD 20.42	-100.0%

Odonate sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2021-09-30	36.4%
Q4	2021-12-31	113.1%
Q3	2022-09-30	N/A
Q4	2022-12-31	-88.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2022YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$53.00K

+79.9%

Gross Margin

0.00%

N/A

Market Cap

$54.85B

N/A

Market Cap/Employee

$400.35M

N/A

Employees

137

N/A

Net Income

$4.75M

+121.6%

EBITDA

$5.87M

+127.3%

Quarterly Fundamentals

Name

Q4 2022YOY CHG

Total Cash

$48.20M

-56.2%

Total Debt

$2.77M

-44.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$2.30M

-46.5%

Short Term Debt

$469.00K

-35.7%

Return on Assets

6.63%

N/A

Return on Invested Capital

-0.74%

N/A

Free Cash Flow

$5.47M

+121.9%

Operating Cash Flow

$5.47M

+122.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ESALYEisai Co., Ltd.

ESALYEisai Co., Ltd.$61.51-2.11%

HURATuHURA Biosciences, Inc.

HURATuHURA Biosciences, Inc.$2.12+1.20%

IMUNImmune Therapeutics, Inc.

IMUNImmune Therapeutics, Inc.$0.09-7.00%

GLSHQGelesis Holdings, Inc.

GLSHQGelesis Holdings, Inc.$0.00+0.00%

GNBTGenerex Biotechnology Corporation

GNBTGenerex Biotechnology Corporation$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$114.92+0.06%

NVDANvidia

NVDANvidia$218.99-0.00%

TTDThe Trade Desk

TTDThe Trade Desk$17.67-0.07%

SOUNSoundHound AI

SOUNSoundHound AI$7.08+0.10%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.68-0.01%

INTCIntel

INTCIntel$99.81-0.01%

PATHUiPath

PATHUiPath$14.00+0.01%

Questions About ODTC

What is the current price of Odonate?

Odonate is trading at $50,000.00 per share.

What is the 52-week range for Odonate?

Over the past 52 weeks, Odonate has traded between $150,000.00 and $150,000.00.

How much debt does Odonate have?

As of the most recent reporting period, Odonate reported total debt of $2.30M.

How much cash does Odonate have on hand?

Odonate reported $39.54M in cash and cash equivalents in its most recent financial results.

What is Odonate’s dividend yield?

Odonate does not currently have a dividend yield.

Odonate(OTC) ODTC

Odonate Financials at a Glance

ODTC News

Why Odonate Therapeutics Stock Is Crashing Today

Why Odonate Therapeutics Stock Is Soaring Today

Here's Why Odonate Therapeutics Stock Jumped 70.7% in June

3 Biotech Stocks That Soared This Week: Are They Buys?

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Odonate

ODTC Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Odonate Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ODTC

What is the current price of Odonate?

What is the 52-week range for Odonate?

How much debt does Odonate have?

How much cash does Odonate have on hand?

What is Odonate’s dividend yield?

Premium Investing Services